Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Urothelial Cancer Vaccine in Advanced Urothelial Cancer
NCT03197571Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021, ETBX-051 in urothelial carcinoma (UC), sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011ETBX-021ETBX-051
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03197571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197571.